BRAF and non-small cell lung carcinoma: However, recent phase II clinical trials have postulated the clinical efficacy of BRAF inhibitor dabrafenib in combination with the MAPK kinase inhibitor trametinib as a therapeutic approach in metastatic BRAF V600E-mutated NSCLC.